top of page
Industry News
From new product launches and strategic partnerships to regulatory shifts, the in vitro economic and regulatory landscape is evolving rapidly.
This is where you'll step ahead on trends and identify new opportunities for your projects.
Muotri Lab brain organoids laid the foundation for Pitt Hopkins syndrome gene therapy trial
31 January 2026 Mahzi Therapeutics-sponsored Phase 1/2 study to assess safety and efficacy of MZ-1866 gene therapy for children and adults with Pitt Hopkins syndrome is about to start. The trial was announced by Mahzi in 2025, highlighting the sponsor's collaboration with the Pitt Hopkins Research Foundation and the Muotri Lab at UC San Diego in developing this long awaited treatment. Pitt-Hopkins syndrome (PHS) is a rare genetic disorder caused by mutations in the tran
Hesperos' CIDP-on-chip evidence instrumental to achieving orphan drug designation
30 June 2025 The Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to riliprubart for treating chronic inflammatory demyelinating polyneuropathy (CIDP), Sanofi reports . Riliprubart also holds this designation for CIDP in the EU and US. By engineering its human-relevant CIDP-on-chip as preclinical tool for disease modelling and drug efficacy testing, Hesperos has played an instrumental role in achieving this outcome. CIDP is an inflamma
Qureator's tumor-on-chip featured in world's first animal-free IND approval
27 October 2025 As we enter a new era of drug discovery, where IND authorization can now be granted based on human data only, marking a clean departure from mandatory animal testing, Qureator's human organ-on-chip platform has laid the groundwork for the world’s first IND approval of its kind . The IND grant concerns SillaJen's BAL0891-tislelizumab combination therapy to treat solid tumors. Qureator's patient-derived vascularized tumor-immune microenvironment (TME) model
Clinical Trial Authorizations
Grants Awarded & Funds Raised
Hesperos establishes strategic sales partnership with AsedaSciences
17 December 2025 Hesperos announces the establishment of a strategic channel sales and marketing partnership with AsedaSciences, offering its pharmaceutical, cosmetic, nutraceutical and chemical industry clients a powerful combination of human-based, in silico and in vitro tools for development of safer compounds. Traditionally, compound safety has been assessed using animal testing, but these models raise ethical concerns, lack human physiological relevance, and offer l
Prellis Biologics joins forces with Eli Lilly to accelerate the discovery of human antibodies
24 September 2025 Berkeley-based Prellis Biologics, Inc. , developer of human in vitro antibody generation platform, announces collaboration with Eli Lilly to accelerate the discovery of human antibodies for multiple disease targets. Prellis’ EXIS™ lymph node platform for target‑specific human antibody generation is a shining example of ingenuity by which several technologies were combined to capture human-relevant physiology. The traditional method of antibody generat
Heartbeat.bio partners with Boehringer Ingelheim to develop a gene therapy for cardiomyopathy
23 September 2025 Vienna-based Heartbeat.bio , developer of breakthrough therapies for cardiac disorders through its proprietary human-based in vitro cardioid drug discovery platform, announces it has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies. Genetic cardiac pathologies such as hypertrophic, dilated, arrhythmogenic right ventricular and restrictive cardiomyopathy, are typically c
Collaborations
bottom of page